The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available 1 .
Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens 2 .
Human cancer cell lines represent a mainstay of tumour biology and drug discovery through facile experimental manipulation, global and detailed mechanistic studies, and various high-throughput applications. Numerous studies have used cell-line panels annotated with both genetic and pharmacological data, either within a tumour lineage [3] [4] [5] or across multiple cancer types [6] [7] [8] [9] [10] [11] [12] . Although affirming the promise of systematic cell line studies, many previous efforts were limited in their depth of genetic characterization and pharmacological interrogation.
To address these challenges, we generated a large-scale genomic data set for 947 human cancer cell lines, together with pharmacological profiling of 24 compounds across ,500 of these lines. The resulting collection, which we termed the Cancer Cell Line Encyclopedia (CCLE), encompasses 36 tumour types ( Fig. 1a and Supplementary Table 1 ; see also http://www.broadinstitute.org/ccle). All cell lines were characterized by several genomic technology platforms. The mutational status of .1,600 genes was determined by targeted massively parallel sequencing, followed by removal of variants likely to be germline events (Supplementary Methods). Moreover, 392 recurrent mutations affecting 33 known cancer genes were assessed by mass spectrometric genotyping 13 ( Supplementary Table 2 and Supplementary Fig. 1 ). DNA copy number was measured using high-density single nucleotide polymorphism arrays (Affymetrix SNP 6.0; Supplementary Methods). Finally, messenger RNA expression levels were obtained for each of the lines using Affymetrix U133 plus 2.0 arrays. These data were also used to confirm cell line identities (Supplementary Methods and Supplementary Figs 2 -4) .
We next measured the genomic similarities by lineage between CCLE lines and primary tumours from Tumorscape 14 , expO, MILE and COSMIC data sets ( Fig. 1b-d and Supplementary Methods). For most lineages, a strong positive correlation was observed in both chromosomal copy number and gene expression patterns (median correlation coefficients of 0.77, range 5 0.52-0.94, P , 10 215 , for copy number, and 0.60, range 5 0.29-0.77, P , 10 215 , for expression, respectively; Fig. 1b , c and Supplementary Tables 3 and 4 ), as has been described previously [3] [4] [5] 15 . A positive correlation was also observed for point mutation frequencies (median correlation coefficient 5 0.71, range 5 20.06-0.97, P , 10 22 for all but 3 lineages; Supplementary Fig. 5 ), even when TP53 was removed from the data set (median correlation coefficient 5 0.64, range 5 20.31-0.97, P , 10 22 for all but 3 lineages; Fig. 1d and Supplementary Table 5 ). Thus, with relatively few exceptions (Supplementary Information), the CCLE may provide representative genetic proxies for primary tumours in many cancer types.
Given the pressing clinical need for robust molecular correlates of anticancer drug response, we incorporated a systematic framework to ascertain molecular correlates of pharmacological sensitivity in vitro. First, 8-point dose-response curves for 24 compounds (targeted and cytotoxic agents) across 479 cell lines were generated (Supplementary  Tables 1 and 6 , and Supplementary Methods). These curves were represented by a logistical sigmoidal function with a maximal effect level (A max ), the concentration at half-maximal activity of the compound (EC 50 ), a Hill coefficient representing the sigmoidal transition, and the concentration at which the drug response reached an absolute inhibition of 50% (IC 50 ).
Broadly active compounds, exemplified by the HDAC inhibitor LBH589 (panobinostat), showed a roughly even distribution of A max and EC 50 values across most cell lines ( Fig. 2a ). In contrast, the RAF inhibitor PLX4720 had a more selective profile: A max or EC 50 values for most cell lines could be categorized as 'sensitive' or 'insensitive' to PLX4720, with sensitive lines enriched for the BRAF V600E mutation ( Fig. 2a ). To capture simultaneously the efficacy and potency of a drug, we designated an 'activity area' ( Fig. 2b and Supplementary Fig. 6 ). The 24 compounds profiled showed wide variations in activity area, and those with similar mechanisms of action clustered together (Supplementary Fig. 7 ).
Genomic correlates of drug sensitivity may be extracted by predictive models using machine learning techniques 6, 10 . We therefore assembled all CCLE genomic data types into a matrix wherein each feature was converted to a z-score across all lines (Supplementary Methods). Next, we adapted a categorical modelling approach that used a naive Bayes classification and discrete sensitivity calls, or an elastic net regression analysis 16 for continuous sensitivity measurements. Both approaches were applied to all compounds and genomic data with or without gene expression features (Supplementary Methods). Prediction performance was determined using tenfold cross-validation, and the elastic net features were bootstrapped to retain only those that were consistent across runs (Supplementary Methods).
Out of .50,000 input features, the regression-based analysis identified multiple known features as top predictors of sensitivity to several agents (Supplementary Table 7 and Supplementary Figs 8 and 9 ), with robust cross-validated performance ( Supplementary Fig. 10 and 11 ). For example, activating mutations in BRAF and NRAS were among the top four predictors of sensitivity in models generated for the MEK inhibitor PD-0325901 (ref. 10) ( Fig. 2c ). Additional predictive features for MEK inhibition included expression of PTEN, PTPN5 and SPRY2 (which encodes a regulator of MAPK output). KRAS mutations were also identified, albeit with a lower predictive value ( Fig. 2c , Supplementary Tables 8 and 9 and Supplementary Fig. 8 ).
Other top predictors included EGFR mutations and ERBB2 amplification/overexpression for erlotinib 8 20) sensitivity. Variants affecting the EXT2 gene, which encodes a glycosyltransferase involved in heparin sulphate biosynthesis, were significantly correlated with erlotinib effects ( Supplementary Fig. 12 ). This observation is intriguing in light of a report linking heparin sulphate with erlotinib sensitivity 21 . In addition, NQO1 expression was identified as the top predictive feature for sensitivity to the Hsp90 inhibitor 17-AAG, a quinone moiety metabolized by NAD(P)H:quinone oxidoreductase (NQO1). NQO1 produces a high-potency intermediate (17-AAGH2) 22 , and has previously been identified as a potential biomarker for Hsp90 inhibitors 23 .
Because some genetic/molecular alterations occur commonly in specific tumour types, lineage may become a confounding factor in predictive analyses. Indeed, a classifier built using the entire cell-line data set performed suboptimally when applied exclusively to melanoma-derived cell lines ( Fig. 2d ), whereas a model built with only melanoma cell lines performed better ( Fig. 2d ). Predictive features in the melanoma-only model showed a strong overexpression of genes regulated by the transcription factors MITF and SOX10 (Supplementary Table 10 ), which may also help predict RAF inhibitor drug sensitivity in melanoma cell lines.
Nonetheless, lineage emerged as the predominant predictive feature for several compounds. For example, elastic net studies of the HDAC inhibitor panobinostat identified haematological lineages as predictors of sensitivity ( Fig. 2e and Supplementary Fig. 9 ). Interestingly, most clinical responses to panobinostat and related compounds (for example, vorinostat and romidepsin) have been observed in haematological cancers. Similarly, most multiple myeloma cell lines ( RESEARCH LETTER AEW541 ( Fig. 2f and Supplementary Figs 8 and 9 ) and showed high IGF1 expression ( Fig. 2f ). Interestingly, elevated IGF1R expression also correlated with AEW541 sensitivity ( Supplementary Fig. 9 ). The CCLE results indicate that multiple myeloma may be a promising indication for clinical trials of IGF1 receptor inhibitors 24 and that these drugs may have enhanced efficacy in cancers with high IGF1 or IGF1R expression. Whereas BRAF and NRAS mutations are known single-gene predictors of sensitivity to MEK inhibitors, several 'sensitive' cell lines lacked mutations in these genes, whereas other lines harbouring these mutations were nonetheless 'insensitive' (Fig. 2c) . The elastic net regression model derived from the subset of cell lines with validated NRAS mutations identified elevated expression of the AHR gene (which encodes the aryl hydrocarbon receptor) as strongly correlated with sensitivity to the MEK inhibitor PD-0325901 ( Fig. 3a) . This finding was interesting in light of previous studies indicating that a related MEK inhibitor (PD-98059) may also function as a direct AHR antagonist 25 . We therefore hypothesized that the enhanced sensitivity of some NRAS-mutant cell lines to MEK inhibitors might relate to a coexistent dependence on AHR function.
To test this hypothesis, we first confirmed the correlation between AHR expression and sensitivity to MEK inhibitors in a subset of NRAS-mutant cell lines ( Fig. 3b and Supplementary Fig. 13 ). Next, we performed short hairpin RNA (shRNA) knockdown of AHR in cell lines with high or low AHR expression ( Fig. 3c ). Silencing of AHR suppressed the growth of three NRAS-mutant cell lines with elevated AHR expression ( Fig. 3d-f ), but had no effect on the growth of two lines with low AHR expression ( Fig. 3g, h) . The growth inhibitory effect was confirmed with two additional shRNAs, where evidence for dose dependence was also apparent (Fig. 3i, j) . We also tested the hypothesis that allosteric MEK inhibitors may suppress AHR function by measuring the effect of PD-0325901 and PD-98059 on endogenous CYP1A1 mRNA, a transcriptional target of AHR in some contexts. Both compounds reduced CYP1A1 levels in NRAS-mutant melanoma cells (IPC-298 and SK-MEL-2; Fig. 3k ) but not in neuroblastoma cells (CHP-212; Fig. 3k ), indicating that other factors may govern CYP1A1 expression in the latter lineage. Together, these results suggest that AHR dependency may co-occur with MAP kinase activation in some NRAS-mutant cancer cells, and that elevated AHR may serve as a 
LETTER RESEARCH
mechanistic biomarker for enhanced MEK inhibitor sensitivity in this setting. We also looked for markers predictive of response to several conventional chemotherapeutic agents ( Supplementary Fig. 7 and Supplementary Table 6 ) and identified SLFN11 expression as the top correlate of sensitivity to irinotecan (Fig. 4a) , a camptothecin analogue that inhibits the topoisomerase I (TOP1) enzyme. SLFN11 expression also emerged as the top predictor of topotecan sensitivity (another TOP1 inhibitor; Supplementary Figs 8 and 14) . Overall, 12 of 16 lineages showed significant SLFN11 associations for topotecan or irinotecan sensitivity (Pearson's r $ 0.2, Supplementary Fig. 14b ). This finding was independently validated using data from the NCI-60 collection ( Supplementary Fig. 15 ). SLFN11 knockdown did not affect steady-state growth sensitivity profiles ( Supplementary Fig. 14d-f ). 
RESEARCH LETTER
All three Ewing's sarcoma cell lines screened showed both high SLFN11 expression and sensitivity to irinotecan ( Fig. 4b and Supplementary Fig. 14) . Ewing's sarcomas also exhibited the highest SLFN11 expression among 4,103 primary tumour samples spanning 39 lineages (Fig. 4c ), suggesting that TOP1 inhibitors might offer an effective treatment option for this cancer type. Towards this end, several ongoing trials in Ewing's sarcoma are examining irinotecanbased combinations, or the addition of topotecan to standard regimens 26 . For some lineages with high SLFN11 expression (for example, cervical adenocarcinoma), topoisomerase inhibitors already comprise a standard chemotherapy regimen. In other tumours where topoisomerase inhibitors are commonly used (for example, colorectal and ovarian cancers), a range of SLFN11 expression was observed, raising the possibility that high SLFN11 expression might enrich for tumours more likely to respond. If confirmed in correlative clinical studies, SLFN11 expression may offer a means to stratify patients for topoisomerase inhibitor treatment.
By assembling the CCLE, we have expanded the process of detailed annotationofpreclinicalhumancancermodels(http://www.broadinstitute. org/ccle). Genomic predictors of drug sensitivity revealed both known and novel candidate biomarkers of response. Even within genetically defined sub-populations-or when agents were broadly active without clear genetic targets-elastic net modelling studies identified key predictors or mechanistic effectors of drug response. Additional efforts that increase the scale and provide complementary types of information (for example, whole-genome/transcriptome sequencing, epigenetic studies, metabolic profiling or proteomic/phosphoproteomic analysis) should enable additional insights. In the future, comprehensive and tractable cell-line systems provided through this and other efforts 27 may facilitate numerous advances in cancer biology and drug discovery.
METHODS SUMMARY
A total of 947 independent cancer cell lines were profiled at the genomic level (data available at http://www.broadinstitute.org/ccle and Gene Expression Omnibus (GEO) using accession number GSE36139) and compound sensitivity data were obtained for 479 lines ( Supplementary Table 11 ). Mutation information was obtained both by using massively parallel sequencing of .1,600 genes ( Supplementary  Table 12 ) and by mass spectrometric genotyping (OncoMap), which interrogated 492 mutations in 33 known oncogenes and tumour suppressors. Genotyping/copy number analysis was performed using Affymetrix Genome-Wide Human SNP Array 6.0 and expression analysis using the GeneChip Human Genome U133 Plus 2.0 Array. Eight-point dose-response curves were generated for 24 anticancer drugs using an automated compound-screening platform. Compound sensitivity data were used for two types of predictive models that used the naive Bayes classifier or the elastic net regression algorithm. The effects of AHR expression silencing on cell viability were assessed by stable expression of shRNA lentiviral vectors targeting either this gene or luciferase as control. The effect of compound treatment on AHR target gene expression was assessed by quantitative RT-PCR. A full description of the Methods is included in Supplementary Information.
